Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03246451
Other study ID # UHG-CFD-METEX
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2017
Est. completion date December 10, 2017

Study information

Verified date July 2018
Source University Hospital, Gentofte, Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Delineation of the role of glucagon-like peptide-1 receptor signalling in the glucose-lowering effect of metformin during meal ingestion in patients with type 2 diabetes.


Description:

Aim: To evaluate the contribution of metformin-induced GLP-1 secretion on the glucose-lowering effect of metformin in patients with type 2 diabetes treated with metformin for 14 days. Furthermore, the investigators aim to elucidate the mechanisms by which metformin-induced GLP-1 secretion may affect glucose levels in patients with type 2 diabetes.

Fifteen patients with type 2 diabetes treated with lifestyle intervention and/or metformin as the only glucose-lowering drug will be enrolled in the study. The effect of a 14-day metformin treatment course on postprandial glucose tolerance will be examined with and without infusion of the GLP-1 receptor antagonist exendin9-39 in 15 patients with type 2 diabetes.

The double-blinded, placebo-controlled, randomised, cross-over study consists of four study days with concomitant infusions of A) placebo + placebo, B) placebo + exendin9-39, C) metformin + placebo and D) metformin + exendin9-39.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date December 10, 2017
Est. primary completion date December 10, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Type 2 diabetes for at least three months (diagnosed according to the criteria of the World Health Organization (WHO)), with a HbA1c <58 mmol/mol.

- Caucasian ethnicity

- Lifestyle intervention and/or metformin monotherapy

- Normal haemoglobin

- Age >18 years

- BMI >23 kg/m2 and <35 kg/m2

- Informed and written consent

Exclusion Criteria:

- Liver disease

- Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major intra-abdominal surgery

- Hypo- or hyperphosphataemia

- Reduced kidney function or nephropathy

- Treatment with medicine that cannot be paused for 12 hours

- Intake of antibiotics two months prior to study

- Hypo- or hypercalcaemia

- Hypo- and hyperthyroidism

- Treatment with oral anticoagulants

- Active or recent malignant disease

- Any treatment or condition requiring acute or sub-acute medical or surgical intervention

- Lack of effective birth control in premenopausal women

- Positive pregnancy test on study days in premenopausal women

- Pregnancy

- Women who are breastfeeding

- Any condition considered incompatible with participation by the investigators

- If the subjects receive any antibiotic treatment while included in the study they will be excluded

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo Oral Tablet
2-4 tablets in 14 days
Metformin
1000-2000 mg in 14 days
Saline
9 mg/ml saline infusion during experimental days
Exendin (9-39)
Infusion of GLP-1 receptor antagonist used as a tool during experimental days

Locations

Country Name City State
Denmark Center for Diabetes Research Gentofte Copenhagen

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Gentofte, Copenhagen University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma glucose The difference between the effect of metformin on postprandial glucose tolerance (as assessed by area under curve (AUC) for plasma glucose during a standardised liquid mixed meal test) with and without blockade of GLP-1 signalling by exendin 9-39. Minutes 240
See also
  Status Clinical Trial Phase
Recruiting NCT05081037 - Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS) N/A
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A
Active, not recruiting NCT05505994 - The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin Phase 3
Completed NCT03623113 - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes N/A
Completed NCT03623139 - Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes N/A
Completed NCT03359629 - Spectrophon LTD Glucometry Monitor Accuracy
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Completed NCT02697305 - Incretin Effects of Branched Chain Amino Acids N/A
Completed NCT01737164 - Effect of Age on Glucose and Lipid Metabolism N/A
Terminated NCT00935766 - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries Phase 3
Recruiting NCT03613688 - Effects of Deepure(Pu-erh Tea Extract) on Glycemic Control N/A
Completed NCT04098549 - The Effect of Rapid and Slow Glucose Fall on the Subsequent Glucose Production in People With Type 1 Diabetes N/A
Terminated NCT04031404 - Glucose and Non-Invasive Brain Stimulation N/A
Active, not recruiting NCT03577964 - Development of Pneumonia Due to Alveolar Glucose Levels in Systemic Hyperglycemia
Active, not recruiting NCT03232008 - Canderel:Effects on Blood Glucose Concentration and Appetite Scores N/A
Completed NCT04042142 - Glucagon Resistance in Patients With NAFLD N/A
Active, not recruiting NCT05607745 - Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study N/A
Completed NCT04004273 - Diabetes, Exercise and Liver Fat (DELIVER) N/A
Completed NCT04082923 - Effect of Meal Texture on Glucose-metabolism and Gut Hormone Response After Bariatric Surgery N/A